Page 50 - 南京医科大学学报自然科学版
P. 50
第44卷第1期
· 44 · 南 京 医 科 大 学 学 报 2024年1月
度(87.5%)和特异度(65.6%),为早期预测中重度活 lesterol affect the clinical response of Graves’ophthal⁃
动期 TAO 患者的激素疗效提供一种简单有效的客 mopathy to parenteral corticosteroids[J]. Front Endocri⁃
观方法,帮助患者制定个体化的治疗方案,改善患 nol(Lausanne),2020,11:609895
者的生活质量和疾病预后。 [8] 陈 文,胡 昊,许晓泉,等. T2 mapping 眼外肌定量
测量在甲状腺相关眼病诊断和分期中的应用价值
本研究存在一些不足。第一,这是一项单中心
[J]. 南京医科大学学报(自然科学版),2019,39(1):
回顾性研究,入组患者仅为特定时间内在医院就诊
141-144
的中重度活动期 TAO 患者,样本量较小,仍需要更
[9] GAGLIARDO C,RADELLINI S,MORREALE BUBEL⁃
大样本量的多中心的前瞻性研究来验证;第二,由
LA R,et al. Lacrimal gland herniation in Graves ophthal⁃
于回顾性的特点,本研究缺少眼眶组织的病理学评 mopathy:a simple and useful MRI biomarker of disease
估,未能精准验证血清学参数、影像学参数与患者 activity[J]. Eur Radiol,2020,30(4):2138-2141
眼眶病理学变化之间的对应关系;第三,本研究仅 [10] XU L,LI L,XIE C,et al. Thickness of extraocular muscle
基于眼眶MRI的径线测量,结合功能磁共振成像可 and orbital fat in mri predicts response to glucocorticoid
能进一步提高预测效能。 therapy in Graves’ophthalmopathy[J]. Int J Endocrinol,
综上所述,基于血清 TC 联合眼眶 MRI 参数 2017,2017:3196059
LGH/OFT,有助于在治疗前预测中重度活动期甲状 [11] HU H,XU X Q,CHEN L,et al. Predicting the response to
glucocorticoid therapy in thyroid⁃associated ophthalmopa⁃
腺相关性眼病患者对 GC 的治疗反应,提高临床诊
thy:mobilizing structural MRI ⁃ based quantitative mea⁃
治的可预期性,有助于临床医生制定个体化的诊疗
surements of orbital tissues[J]. Endocrine,2020,70(2):
计划,改善患者预后。
372-379
[参考文献] [12] BARRIO⁃BARRIO J,SABATER A L,BONET⁃FARRIOL
E,et al.Graves’ophthalmopathy:VISA versus EUGOGO
[1] BARTALENA L,KAHALY G J,BALDESCHI L,et al.
classification,assessment,and management[J]. J Oph⁃
The 2021 European Group on Graves ’ orbitopathy
thalmol,2015,2015:249125
(EUGOGO)clinical practice guidelines for the medical
management of Graves’orbitopathy[J]. Eur J Endocrinol, [13] 陈 露,胡 昊,陈 文,等. 常规 MRI 泪腺结构定量
测量在甲状腺相关眼病激素治疗疗效预测中的价值
2021,185(4):G43-G67
[J]. 放射学实践,2021,36(6):728-732
[2] BARTALENA L,PIANTANIDA E,GALLO D,et al. Epi⁃
[14] 王妮妮,胡 昊,陈 文,等. 基于 MRI 眼肌结构量化
demiology,natural history,risk factors,and prevention of
Graves’orbitopathy[J]. Front Endocrinol(Lausanne), 评估甲状腺相关性眼病糖皮质激素脉冲治疗的疗效
[J]. 南京医科大学学报(自然科学版),2019,39(3):
2020,11:615993
343-348
[3] KHONG J J,MCNAB A A,EBELING P R,et al. Patho⁃
[15] 高 松,陈 露,胡 昊,等. Dixon 技术在甲状腺相关
genesis of thyroid eye disease:review and update on mo⁃
lecular mechanisms[J]. Br J Ophthalmol,2016,100(1): 性眼病早期视神经改变评估中的价值[J]. 南京医科大
142-150 学学报(自然科学版),2022,42(4):556-559,577
[4] HIROMATSU Y,EGUCHI H,TANI J,et al. Graves’oph⁃ [16] REGENSBURG N I,WIERSINGA W M,BEREND⁃
thalmopathy:epidemiology and natural history[J]. Intern SCHOT T T,et al. Effect of smoking on orbital fat and
Med Tokyo Jpn,2014,53(5):353-360 muscle volume in Graves’orbitopathy[J]. Thyroid,2011,
[5] VANNUCCHI G,COVELLI D,CAMPI I,et al. The thera⁃ 21(2):177-181
peutic outcome to intravenous steroid therapy for active [17] DEBOSE⁃BOYD R A. Significance and regulation of lipid
Graves’orbitopathy is influenced by the time of response metabolism[J]. Semin Cell Dev Biol,2018,81:97
but not polymorphisms of the glucocorticoid receptor[J]. [18] LANZOLLA G,SABINI E,PROFILO M A,et al. Rela⁃
Eur J Endocrinol,2014,170(1):55-61 tionship between serum cholesterol and Graves’orbitopa⁃
[6] LANZOLLA G,VANNUCCHI G,IONNI I,et al. Choles⁃ thy(GO):a confirmatory study[J]. J Endocrinol Investig,
terol serum levels and use of statins in Graves’orbitopa⁃ 2018,41(12):1417-1423
thy:a new starting point for the therapy[J]. Front Endo⁃ [19] SABINI E,MAZZI B,PROFILO M A,et al. High serum
crinol,2019,10:933 cholesterol is a novel risk factor for Graves’orbitopathy:
[7] NASELLI A,MORETTI D,REGALBUTO C,et al. Evi⁃ results of a cross⁃sectional study[J]. Thyroid,2018,28
dence that baseline levels of low⁃density lipoproteins cho⁃ (下转第129页)